
Keisuke Goto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4109843/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 3936.	4.1	42
2	FGF19 promotes progression of prostate cancer. Prostate, 2015, 75, 1092-1101.	2.3	37
3	Preoperative risk classification using neutrophil–lymphocyte ratio and hydronephrosis for upper tract urothelial carcinoma. Japanese Journal of Clinical Oncology, 2018, 48, 841-850.	1.3	30
4	Clinical staging of upper urinary tract urothelial carcinoma for TÂstaging: Review and pictorial essay. International Journal of Urology, 2019, 26, 1024-1032.	1.0	24
5	Non-coding RNAs are promising targets for stem cell-based cancer therapy. Non-coding RNA Research, 2017, 2, 83-87.	4.6	21
6	Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients. Prostate, 2019, 79, 234-242.	2.3	20
7	PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma. Anticancer Research, 2020, 40, 1943-1951.	1.1	20
8	Accumulation of FGF9 in prostate cancer correlates with epithelial-to-mesenchymal transition and induction of VEGF-A expression. Anticancer Research, 2014, 34, 695-700.	1.1	19
9	Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 795.e1-795.e8.	1.6	17
10	Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 605.e9-605.e17.	1.6	16
11	TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma. Oncology, 2020, 98, 689-698.	1.9	15
12	Fibroblast Growth Factor Family in the Progression of Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 183.	2.4	14
13	BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma. Oncology, 2021, 99, 240-250.	1.9	14
14	Combination therapy using molecularâ€ŧargeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma. Cancer Medicine, 2017, 6, 2308-2320.	2.8	12
15	Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3. Japanese Journal of Clinical Oncology, 2020, 50, 473-478.	1.3	11
16	KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer. Journal of Clinical Medicine, 2021, 10, 4837.	2.4	11
17	Recurrence―and progressionâ€free survival in intermediateâ€risk nonâ€muscleâ€invasive bladder cancer: the impact of conditional evaluation and subclassification. BJU International, 2021, 127, 473-485.	2.5	10
18	Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosis. Abdominal Radiology, 2018, 43, 1540-1545.	2.1	9

Кеізике Сото

#	Article	IF	CITATIONS
19	CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma. Anticancer Research, 2021, 41, 4875-4883.	1.1	9
20	lmaging features of papillary renal cell carcinoma with cystic change-dominant appearance in the era of the 2016 WHO classification. Abdominal Radiology, 2017, 42, 1850-1856.	2.1	8
21	Chronic kidney disease as a risk factor for recurrence and progression in patients with primary nonâ€muscleâ€invasive bladder cancer. International Journal of Urology, 2017, 24, 594-600.	1.0	8
22	Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents. International Urology and Nephrology, 2022, 54, 1225-1232.	1.4	8
23	TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 368.e1-368.e9.	1.6	6
24	P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma. Anticancer Research, 2021, 41, 4287-4294.	1.1	6
25	Prostate cancer detection by prostate-specific antigen-based screening in Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection. Canadian Urological Association Journal, 2014, 8, 327.	0.6	5
26	A case of tubulocystic carcinoma of the kidney with aggressive features. Japanese Journal of Radiology, 2016, 34, 307-311.	2.4	4
27	Anastomosing haemangioma with fatty changes in the perirenal space: a lesion mimicking liposarcoma. BJR case Reports, 2018, 4, 20170022.	0.2	4
28	Longitudinal analysis of retroperitoneoscopic adrenalectomy regarding cosmesis outcomes: comparison of lateral transperitoneal and reduced port laparoscopic adrenalectomy. Updates in Surgery, 2022, 74, 757-764.	2.0	4
29	Histopathological Analysis of False-positive Lesions in mpMRI/TRUS Fusion Prostate Biopsy. In Vivo, 2022, 36, 496-500.	1.3	4
30	Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levels. International Cancer Conference Journal, 2020, 9, 240-243.	0.5	3
31	Tumor contact length of prostate cancer determined by a threeâ€dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence. International Journal of Urology, 2021, 28, 1012-1018.	1.0	3
32	Tumor heterogeneity evaluated by computed tomography detects muscle-invasive upper tract urothelial carcinoma that is associated with inflammatory tumor microenvironment. Scientific Reports, 2021, 11, 14251.	3.3	3
33	Renal metastasis from primary hepatocellular carcinoma: a case report. International Cancer Conference Journal, 2020, 9, 141-145.	0.5	2
34	HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer. Biomedicines, 2021, 9, 893.	3.2	2
35	Comparison of Chief Surgeons' and Assistants' Feelings of Fatigue Between Laparoendoscopic Singleâ€site and Conventional Laparoscopic Adrenalectomy. World Journal of Surgery, 2021, 45, 1466-1474.	1.6	1
36	Successful treatment of BK virusâ€associated severe hemorrhagic cystitis with bilateral singleâ€J ureteral stenting. IJU Case Reports, 0, , .	0.3	1

#	Article	IF	CITATIONS
37	The secondary tumor of the prostate derived from upper tract urothelial carcinoma: An autopsy case. IJU Case Reports, 2021, 4, 397-402.	0.3	0